Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Mqv
Neutral
Garp
Very Strong
Mqv Small
Neutral
Value
Consensus
Price
Weak
Earnings
Neutral
Earnings
Very Strong
Dividends
Very Weak
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
Alnylam Pharmaceuticals, Inc
Telephone
1.617.551.8200
Address
Henri A. Termeer Square, 675 West Kendall Street, Cambridge, MA 02142
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 284.19 - 495.55
Trade Value (12mth)
US$113,102,681.00
1 week
2.55%
1 month
-4.58%
YTD
-26.46%
1 year
0.59%
All time high
495.55
EPS 3 yr Growth
-125.80%
EBITDA Margin
15.00%
Operating Cashflow
$524m
Free Cash Flow Return
17.00%
ROIC
10.20%
Interest Coverage
2.20
Quick Ratio
2.70
Shares Outstanding (Fully Diluted)
138m
HALO Sector
Healthcare
Next Company Report Date
18-Feb-27
Next Ex Dividend Date
N/A
Next Dividend Pay Date
N/A
Reporting Currency
USD
Short Sell (% of issue)
0.00
| Date | Announcements |
| 30 April 26 | |
| 30 April 26 | |
| 30 April 26 | |
| 05 March 26 | |
| 05 March 26 |
Historical data
Forecast data
| USD | 2021 | 2022 | 2023 | 2024 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |||
| Per Share, Growth & Valuations | |||||||||||||
EPS (Basic) | $ |  | | | | -3.52 | -2.18 | 2.39 | | | | ||
EPS (Fully Diluted) | $ | | | | | -3.52 | -2.18 | 2.33 | | | | ||
Growth | % | | | | | 62.1 | 38.2 | 209.9 | | | | ||
PE | X | | | | | N/A | N/A | 170.7 | | | | ||
EV/EBITDA | X | | | | | N/A | N/A | 95.7 | | | | ||
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
